App-Quantinova.ai

Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Pooja Ghatalia - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Cabozantinib

Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Pooja Ghatalia - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Pancreatitis

Cabozantinib

A phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors.

Jason Edward Faris - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pancreatic Neuroendocrine Tumors

Cabozantinib

Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.

Andrea Borghese Apolo - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Cabozantinib

Met signaling in urothelial carcinoma of the bladder.

Donald P Bottaro - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cabozantinib

Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials.

Jeffrey J. Leow - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertension

Cabozantinib

Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR).

Toni K. Choueiri - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

Cabozantinib

Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.

Christopher Sweeney - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Fatima Karzai - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219): Evaluation of bone metastasis microenvironment.

Petros Grivas - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

Cabozantinib

A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating tumor cells and large oncosomes.

Edwin M. Posadas - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.

Michelle Wilson - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

Cabozantinib

Personalized cancer therapy for patients with metastatic medullary thyroid cancer (MTC).

Krzysztof Misiukiewicz - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thyroid Cancer

Cabozantinib

Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).

Ghassan K. Abou-Alfa - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

A phase II trial of cabozantinib (XL-184) in patients with advanced cholangiocarcinoma.

Lipika Goyal - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cabozantinib

Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).

Ghassan K. Abou-Alfa - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Matthew Raymond Smith - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Ethan M. Basch - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial.

Raya Leibowitz-Amit - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Fatima Karzai - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Filters

366 Abstracts